Abstract
The development of fractional-dose inactivated poliovirus vaccine (fIPV) has been crucial to the global polio eradication initiative (GPEI) in the past decade, providing a dose-stretching and affordable option to enable global inactivated poliovirus vaccine (IPV) introduction. In April, 2016, the type 2 component of oral poliovirus vaccine (OPV) was withdrawn from routine immunisation because of the risk of vaccine-derived poliovirus and vaccine-associated paralytic poliomyelitis, and the trivalent OPV was replaced with a bivalent form.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
